Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

In the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Patients on stable treatment with mycophenolate for at least 6 mon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet respiratory medicine 2021-01, Vol.9 (1), p.96-106
Hauptverfasser:	Highland, Kristin B, Distler, Oliver, Kuwana, Masataka, Allanore, Yannick, Assassi, Shervin, Azuma, Arata, Bourdin, Arnaud, Denton, Christopher P, Distler, Jörg H W, Hoffmann-Vold, Anna Maria, Khanna, Dinesh, Mayes, Maureen D, Raghu, Ganesh, Vonk, Madelon C, Gahlemann, Martina, Clerisme-Beaty, Emmanuelle, Girard, Mannaig, Stowasser, Susanne, Zoz, Donald, Maher, Toby M
Format:	Artikel
Sprache:	eng
Schlagworte:	Disease Progression Double-Blind Method Female Human health and pathology Humans Indoles - adverse effects Indoles - therapeutic use Life Sciences Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Male Middle Aged Mycophenolic Acid - therapeutic use Pharmaceutical sciences Pharmacology Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pulmonology and respiratory tract Scleroderma, Systemic - complications Scleroderma, Systemic - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!